Genta Incorporated Announces Conference Call To Discuss Third Quarter 2002 Earnings
BERKELEY HEIGHTS, N.J., Oct 31, 2002 /PRNewswire-FirstCall via COMTEX/ -- Genta
Incorporated (Nasdaq: GNTA) announced it will hold a conference call on
Thursday, November 7, 2002 at 8:00 AM EST to discuss third-quarter 2002 earnings
and company highlights. Dr. Raymond P. Warrell, Jr., Genta's Chairman and CEO,
will host the conference call.
The conference call can be accessed as follows:
U.S./Canada: Dial (888) 529-1867, reference Genta
International: Dial (706) 643-1282, reference Genta
Or via the web through Genta's investor site at:
genta.com.
A replay will be available after the completion of the conference call and is
accessible via streaming media through the company's investor relations site at
genta.com.
Genta Incorporated is a biopharmaceutical company with a diversified product
portfolio that is focused on anticancer therapy. The Company's research platform
is anchored by DNA medicines, particularly applications of antisense and decoy
aptamer technology. Genasense(TM), the Company's lead compound, has received
"Fast Track" and "Orphan Drug" designation from the Food and Drug
Administration. Genasense(TM) is currently undergoing late-stage, Phase 3
clinical testing in several clinical indications. Genta's pipeline also
comprises a portfolio of small molecules, including gallium-containing compounds
and Androgenics compounds. Genta aims to become a direct marketer of its
pharmaceutical products in North America. For more information about Genta,
please visit our website at: www.genta.com. |
